Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience

J Sastre
Journal of Investigational Allergology & Clinical Immunology 2019 April 12
Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy, and H1-antihistamines, which stabilise the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established oral second-generation H1-antihistamine. It is administered once daily at a dose of 10-20 mg and is available as a standard tablet and also as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has demonstrated to be efficacious at relieving symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. Ebastine has modulating effects on the allergic inflammatory process in addition to its antihistamine effects, which may help explain the beneficial effect it has on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, confirmed after decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Trending Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"